Skip to main content

Advertisement

Table 1 Patient demographics

From: Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Characteristics Specification Value (%)
Age, years Mean ± Std 51.0 ± 9.3
Min~Max 28.1.70.1
Gender Male 21 (58.3)
Female 15 (41.7)
Tumor histology Melanoma 22 (61.1)
Urothelial carcinoma 8 (22.2)
Renal cell carcinoma 6 (16.7)
ECOG PS 0 16 (44.4)
1 20 (55.6)
PD-L1 expression* Positive 16 (44.4)
Negative 12 (33.3)
NA 8 (22.2)
Prior therapies Chemotherapy 36 (100.0)
Surgery 34 (94.4)
Radiation therapy 7 (19.4)
  1. Age, gender, histology, ECOG performance score, PD-L1 expression on tumor biopsy by IHC staining, and prior therapies were summarized. *PD-L-positive status was defined as the presence of membrane staining of any intensity in ≥ 1% of tumor cells